Osteoporosis News

Low vitamin B12 levels in the blood were found to increase the risk of fracture in older Swedish men, according to study results published in Osteoporosis International.

The Bone Health Collaborative announced the launch of a Fracture Liaison Service Demonstration Study to provide participating hospitals with the cloud-based platform to assess the adoption and implementation of the fracture liaison service.

Patients taking denosumab to treat osteoporosis found a higher mean increase in spine bone mineral density, while patients treated with zoledronic acid had an increase in flu-like symptoms while taking the drug, according to researchers from Loyola University and the University of Notre Dame.

Non-hip, non-vertebral fractures increase the risk of mortality, and the risk is higher in men than women, according to a recent study from researchers in Australia.

The International Osteoporosis Foundation (IOF) has released a position paper that identifies cancer patients as most at risk for bone disease and fractures and outlines recommendations from different societies on fracture prevention for these patients.

Researchers found osteoporosis was a significant risk factor in this study of scapular fracture after reverse shoulder arthroplasty, and that plain radiographs were moderately reliable in determining the presence of scapular fractures after the procedure.

More than 69% of men taking antiepileptic drugs experienced improvements in bone mineral density after supplementation with calcium and vitamin D or calcium and vitamin D plus risedronate, according to recently published data.

The International Osteoporosis Foundation has released a report which predicted an increase in the number of people with osteoporosis in the European Union from 27.5 million people to 33.9 million people by 2025.

The common practice of administering vitamin D supplementation for the prevention of osteoporosis among adults may be unnecessary, according to data reported in The Lancet.

BALTIMORE — Patients previously treated with an oral bisphosphonate who still have a high risk for fracture may benefit from transitioning to denosumab, according to data presented at ASBMR 2013.